Open-Source Antibodies for Biomedical Research

🔍 The antibody reproducibility crisis continues to challenge biomedical research. Across labs worldwide, time and money is lost to antibodies that don't perform consistently. To address this challenge, YCharOS Inc. (Antibody Characterization through Open Science) was founded to bring consistency, transparency, and open access to antibody validation data. Through a standardized, knockout-based workflow, YCharOS systematically tests antibodies from across the industry and freely shares the results for the benefit of all researchers. In addition to its depth of analysis, the breadth of collaboration behind YCharOS is a defining factor in its success. Their approach enables researchers to directly compare antibodies between different vendors. Vendor partnerships with YCharOS demonstrate an ongoing commitment to providing high-quality, reliable research tools and driving transparency and accountability in the antibody marketplace. Aviva Systems Biology is proud to partner with YCharOS in this effort, contributing antibodies for independent testing and publishing the validation data directly on our product pages. Together, we’re driving a more open and reliable scientific ecosystem. Read more at https://lnkd.in/gBZEW6r4 https://hubs.ly/Q03PJhJW0

We’re excited to announce three new Oxford Nanopore long-read services now available at WBL: -Pharmacogenomics (PGx) Panel (RUO): full-gene coverage, including repeats, structural variants, and hybrid alleles often missed by short-read methods. -Telomere Sequencing (RUO): molecule-level resolution of telomere length and subtelomeric methylation across individual chromosome arms. -mRNA Vaccine QC: direct, full-length sequencing of mRNA constructs to assess identity, integrity, and purity in a single-workflow. By combining Oxford Nanopore workflows with WBL’s high-throughput infrastructure and integrated bioinformatics, researchers gain access to advanced long-read capabilities designed to support discovery, translational, and clinical research. Check-out the announcement: https://lnkd.in/e7chNZyd? #WasatchBioLabs #LongReadSequencing #NanoporeSequencing #Genomics #Pharmacogenomics #TelomereSequencing #mRNAVaccineQC

🎬  Bringing Complex Science to Life: Antibody-Drug Conjugates in Motion Their mechanism of action of drugs often involves multiple molecular steps that can be difficult to capture in words or static diagrams. That’s where animation makes the difference, turning complexity into clarity for: · Researchers & clinicians seeking shared understanding · Students & trainees learning advanced mechanisms · Patients & the public seeing innovation in relatable ways · Companies & investors communicating impact with confidence At The Erudite, we believe complex science deserves more than text, it deserves to be seen, understood, and brought to life. ADCs are one of the most exciting frontiers in targeted cancer therapy, combining the precision of antibodies with the power of cytotoxic drugs. Here, our talented animator has created a 2D explanation video, describing how ADCs work: 1. The antibody binds to a tumor-specific antigen. 2. The ADC is internalized and trafficked to lysosomes via the endosome 3. The linker is cleaved (depending on design), releasing the cytotoxic payload. 4. The drug reaches its target, microtubules or DNA, and kills the cancer cell. The antibody acts as a homing missile, ensuring that potent drugs reach tumor cells while sparing healthy tissues! This marks the finale of our #AntibodyInsights series! We’ve explored the landscape, technologies, and future of antibody-based drugs, and with formats like bispecifics, ADCs, and emerging nanobody technologies, the antibody toolbox has only just begun to show its potential. #AntibodyInsights #AntibodyDrugConjugates #ScienceCommunication #Immunotherapy #CancerResearch #Biotech #ScienceAnimation

🧪 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐢𝐧 𝐭𝐡𝐞 𝐒𝐩𝐨𝐭𝐥𝐢𝐠𝐡𝐭: 𝐀 𝐒𝐏𝐀𝐑𝐐-𝐃𝐫𝐢𝐯𝐞𝐧 𝐁𝐫𝐞𝐚𝐤𝐭𝐡𝐫𝐨𝐮𝐠𝐡 𝐟𝐨𝐫 𝐂𝐡𝐢𝐥𝐝𝐡𝐨𝐨𝐝 𝐂𝐚𝐧𝐜𝐞𝐫 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 A collaborative team led by Ferris State University — a proud member of the Shimadzu Scientific Instruments SPARQ program (Shimadzu Partnerships for Academics, Research & Quality of Life) — has developed a robust LC-MS/MS method to quantify a key ALK-inhibitor metabolite in mouse plasma as part of pre-clinical neuroblastoma research. 🔬 𝐖𝐡𝐚𝐭 𝐌𝐚𝐤𝐞𝐬 𝐓𝐡𝐢𝐬 𝐒𝐭𝐚𝐧𝐝 𝐎𝐮𝐭: Ferris State scientists optimized and validated the method on a Shimadzu LCMS-8060NX triple-quadrupole platform, demonstrating high sensitivity, selectivity, and rapid analysis suitable for pre-clinical pharmacokinetic studies in animal models. This research provides valuable data for understanding how ALK-targeted drugs behave during early-stage investigations, paving the way for further translational studies. 🌟 𝐒𝐏𝐀𝐑𝐐 𝐏𝐨𝐰𝐞𝐫𝐬 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧: Shimadzu’s SPARQ flagship program supports Ferris State and other select universities by providing cutting-edge instrumentation, training, and partnership funding to accelerate translational research that enhances scientific understanding and quality of life. 💡 𝐖𝐡𝐲 𝐈𝐭 𝐌𝐚𝐭𝐭𝐞𝐫𝐬: ✅ Expands access to advanced LC-MS/MS tools for cancer-related pharmacology research. ✅ Demonstrates the value of academic–industry partnerships in advancing oncology discoveries. ✅ Provides a research framework that may help inform future precision-dosing strategies in pediatric cancer therapies. 📄 𝐋𝐞𝐚𝐫𝐧 𝐌𝐨𝐫𝐞: Original Manuscript: https://lnkd.in/e_dGs4vA #NeuroblastomaResearch #PreClinicalResearch #LCMSMS #Pharmacokinetics #SPARQ #ShimadzuSPARQ #FerrisStateUniversity #LCMS8060NX #MassSpecForGood #ResearchInTheSpotlight #MassSpectrometry #Shimadzu #LCMS

Anticancer Drug Discovery Based on Natural Products: From Computational Approaches to Clinical Studies 🌿 by Chunarkar-Patil, P., et al. (2024). Biomedicines, 12(1), 201. 📚 Read the full text here: https://brnw.ch/21wWTy0 💊Of the myriad challenges in modern medicine, the fight against cancer remains one of the most urgent, with malignancies claiming one in six lives globally. Despite advances from immunotherapy to precision medicine, the quest for effective, novel treatments is relentless. Here, nature’s molecular library offers a profound and historically proven reservoir for discovery, with compounds like vincristine having already revolutionized care. This review champions the powerful synergy of harnessing these natural products with cutting-edge computational drug discovery—a fusion that is radically accelerating the fight against cancer. By deploying in silico models, researchers can swiftly pinpoint potent agents like betulinic acid, streamlining the path from digital screening to experimental validation in lab and animal studies. The journey from concept to clinic is exemplified by the clinical progression of artemisinin and silvestrol. To overcome existing limitations and unlock nature’s full potential, the integration of deep learning and artificial intelligence is paramount. This vigorous, computationally-driven approach is not merely an enhancement; it is a transformative force, poised to unleash a new generation of powerful and intelligent anticancer therapeutics💻 #MDPI #OpenAccess #Biomedicines #NaturalProducts #AnticancerDrugDiscovery #ComputationalDrugDesign #ClinicalTrials #MolecularDynamics #DrugDevelopment

Not All Research Happens in a Lab — Here’s How It All Connects Ever wonder how research moves from the lab to real-world impact? 🤔 From basic discovery to patient care, every stage plays a vital role in advancing science. Here’s a breakdown of the different types of research (with a few examples from my own experience): 🔬 Bench (Basic) Research This is where it all begins — in the lab. Scientists explore cellular mechanisms, genetics, and molecular pathways to uncover how diseases work. Example: Testing how specific proteins or receptors behave in cancer cells, or studying mechanisms behind drug resistance and tumor growth. 🔁 Translational Research Often called “bench to bedside,” translational research bridges laboratory findings with patient-focused applications. Example: Taking discoveries from preclinical studies — like identifying how certain cancer pathways contribute to treatment resistance — and using that data to guide early-phase drug development. I’ve worked on studies exploring novel antibody-drug conjugates (ADCs) and targeted therapies, focused on understanding how new mechanisms of action can improve outcomes for patients with treatment-resistant cancers. 🧍♀️ Clinical Research This is the phase most people are familiar with — where new therapies, diagnostics, or interventions are tested directly in patients. Example: Overseeing clinical trials that evaluate immunotherapy combinations, precision oncology drugs, and new treatment sequencing strategies to determine which approaches work best for specific patient populations. It’s where hypotheses are validated, and science meets patient care. 🌍 Population / Epidemiological Research This focuses on trends, outcomes, and risk factors across large groups. Example: Using data analytics tools like TriNetX or Epic SlicerDicer to study patterns — such as what predicts treatment side effects, or which patient characteristics are associated with better survival outcomes. These insights often inform future clinical trial design and public health strategies. 💡 Why It Matters Each type of research plays a crucial role in advancing medicine. Bench research uncovers mechanisms, translational bridges the gap, clinical brings discoveries to patients, and population research guides prevention and policy. Together, they form a continuous cycle that drives innovation and improves lives. ✨ Whether you’re in the lab, the clinic, or the data world — you’re part of a larger ecosystem of discovery. #ClinicalResearch #TranslationalScience #OncologyResearch #DigitalHealth #BenchToBedside #Oncology #Hematology #Pharma #Biopharma #MedDevice

🔬 Immunofluorescence (IF) is a microscopy technique used to detect and localize specific biomolecules such as proteins or antigens within cells or tissues by using antibodies conjugated to fluorescent dyes (fluorophores). 🔬 When the fluorophores are excited by light of a specific wavelength, they emit light at a different wavelength, which can be visualized using a fluorescence microscope. 🔬 This method is based on the high specificity of antigen-antibody binding, allowing precise visualization of target molecules. 🔬 There are two main types of immunofluorescence staining: direct and indirect. 🔬 In direct immunofluorescence, the antibody that binds to the target antigen is directly labeled with a fluorophore, making it a simpler and faster method. 🔬 Indirect immunofluorescence uses an unlabeled primary antibody to bind the antigen, followed by a fluorophore-labeled secondary antibody that binds to the primary antibody. 🔬 The indirect method offers greater sensitivity because multiple secondary antibodies can bind to a single primary antibody, amplifying the signal. 🔬 Immunofluorescence is widely used in research and clinical diagnostics for studying protein distribution, detecting infections, autoimmune diseases, and more. It can be performed on various sample types including cultured cells, tissue sections, or cell suspensions, and often requires fixation and permeabilization of cells to preserve structure and allow antibody access. 🏢 At Sama Tashkhis Aria, we offer a wide range of high-quality immunofluorescence antibodies to support advanced research and diagnostic applications. 🏢 Our products are carefully selected to ensure precision, reliability, and excellence for use in various immunofluorescence techniques. 🏢 Whether for clinical diagnostics or scientific investigation, we provide reagents that meet the highest standards. 📍 For inquiries and orders, please contact us at: ☎️: 021 8833 3215-16 📧: samatashkhis@domain.com 🌐: samatashkhis.com #immunofluorescence #IF #Laboratory #Immunology #Genetics #Biology #Microscope #fluorescence

Antibody Therapeutics (IF=4.5, Oxford University Press) 🚀 Deep Learning Meets Immunology: TransMHCII A fascinating review published in Antibody Therapeutics introduces TransMHCII, a novel MHC-II binding prediction model that combines protein language models (PLMs) with image classifiers. Authors: Xin Yu,Christopher Negron,Lili Huang,and Geertruida Veld from AbbVie Bioresearch Center By integrating architectures from image recognition (like EfficientNet and ViT) with PLMs (ESM1b, ProtXLNet, ProtT5-XL-UniRef), TransMHCII significantly outperforms existing tools such as NetMHCIIpan 3.2 and 4.0 in predicting peptide–MHC II binding affinity. This study highlights how transfer learning and cross-domain AI can open new frontiers for biological prediction models — bridging protein structure understanding with machine learning innovation. 🔗 Read more: https://lnkd.in/g6VZcjBP #antibody #antibodies #antibodytherapeutics #DeepLearning #Immunology #Bioinformatics #ProteinLanguageModel #MHC #MachineLearning #ComputationalBiology

Computational Methods in Immunoinformatics: Epitope Discovery and Diagnostic Applications. https://hubs.ly/Q03MzfC50 A recent review highlights how immunoinformatics, the integration of experimental immunology with computational prediction, can accelerate the identification of diagnostic and therapeutic epitopes using AI-driven modeling and structural analysis. While such frameworks are well-developed in vaccine design, the study emphasizes the need for standardized pipelines for diagnostic applications, combining predictive algorithms with experimental validation. At CovalX, our Epitope Mapping services bridge this crucial gap by experimentally validating computational predictions through HDX-MS and XL-MS, providing high-resolution insight into antigen–antibody interactions that strengthen both diagnostic and therapeutic development. https://hubs.ly/Q03MznRc0

The Influenza A virus (IAV) is responsible for 12-52k deaths annually in the U.S., but it is challenging to fight because IAV changes its genetic makeup to resist antiviral treatments. Additionally, if scientists develop new therapeutics, there isn’t a suitable human in vitro model for testing.   A new Wyss Institute at Harvard University study demonstrates how Human Organ Chip technology can be used to safely and effectively test next-generation CRISPR RNA therapies that broadly target strains of IAV. This effort is a collaboration between the labs of Natalie Artzi and Donald Ingber, M.D., Ph.D. They report that this treatment reduced viral load by more than 50% and significantly lowered inflammation, with minimal off-target effects. This is a major step toward broad-spectrum flu therapies.    https://lnkd.in/ddzfand8